Here’s a groundbreaking revelation that could change the game for kidney cancer patients: A significant number of individuals battling kidney cancer with brain metastases are experiencing prolonged survival and tumor control, thanks to a treatment that’s turning heads in the medical community. But here’s where it gets even more intriguing—this isn’t just about extending life; it’s about challenging the status quo of how we approach this aggressive disease. Let’s dive into the details.
At the International Kidney Cancer Symposium (IKCS) in Denver, researchers unveiled promising findings from a small prospective study involving cabozantinib (Cabometyx). Among 25 patients with non-locally treated brain metastases from kidney cancer, 56% remained free of metastatic progression for at least 6 months, with a remarkable 71% response rate in those with fumarate hydratase-deficient renal cell carcinoma (FH-dRCC). This is no small feat, considering that patients with brain metastases from kidney cancer have historically faced grim prognoses and have often been excluded from clinical trials.
But here’s where it gets controversial: While local therapies like surgery or radiation remain the standard of care for brain metastases, these findings suggest that systemic treatments like cabozantinib could offer a viable—and perhaps even superior—alternative for certain patients. Could this shift the paradigm for how we treat this challenging condition? The debate is far from over.
In the CABRAMET trial, a phase II multicenter study, 26 patients with metastatic RCC and non-locally treated brain metastases received cabozantinib. The results were striking: 61% of patients achieved an overall response, with 56% showing no progression at 6 months. Median progression-free survival (PFS) was 8.1 months, and brain metastasis PFS reached an impressive 10.7 months. Even more compelling, 58.3% of patients had ongoing responses, and 21 out of 25 patients experienced some degree of tumor shrinkage. These outcomes were particularly pronounced in patients who had not received prior tyrosine kinase inhibitor (TKI) treatment, raising questions about the optimal sequencing of therapies.
And this is the part most people miss: FH-dRCC, a rare and aggressive subtype of kidney cancer linked to mutations in the FH gene, has long been a treatment conundrum. Until recently, options were limited, with recurrence common even after effective treatments like erlotinib and bevacizumab. However, the combination of cabozantinib and nivolumab (Opdivo) has shown a 71% response rate in a retrospective study, rivaling—and in some cases surpassing—other TKI-immunotherapy combinations like sintilimab plus axitinib and tislelizumab plus lenvatinib. But which combination is truly the best? And what’s the ideal sequence of treatments? These questions remain hotly debated.
For FH-dRCC patients, the results are particularly encouraging. Among 14 patients treated with cabozantinib and nivolumab, 10 achieved partial responses, and two had stable disease, resulting in an 85.7% disease control rate. Median PFS was 15.1 months, and overall survival (OS) reached 37.3 months—numbers that rival those of recent TKI-immunotherapy trials. Yet, the optimal treatment strategy for this rare disease is still up in the air, leaving room for further research and discussion.
Here’s the thought-provoking question for you: As we celebrate these advancements, should we be pushing harder to include brain metastasis patients in clinical trials, or is the focus on systemic treatments like cabozantinib enough to revolutionize care? Share your thoughts in the comments—let’s keep the conversation going.
